

Can high-frequency ultrasound combined computed tomography accurately diagnose thyroid tumor?

A protocol of systematic review and meta-analysis

Lin-hua Zhang, MM^a, Gang Chen, MM^b, Wei Tao, MB^{b,*}

Abstract

Background: Previous clinical studies have reported that clinical value of high-frequency ultrasound combined computed tomography (HFUCT) is used for diagnosis of thyroid tumor (TT). However, no study has investigated this topic systematically. Therefore, this study will evaluate the clinical value of HFUCT for the diagnosis of TT.

Methods: We will search the databases of Cochrane Library, EMBASE, PUBMED, SCOPUS, Web of Science, OpenGrey, Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, and China National Knowledge Infrastructure from any time period published to the present. We will consider all case-controlled studies that assessed the clinical value of HFUCT for diagnosis of TT. Two authors will independently scan titles and abstracts to check eligible studies, followed by full-text read. We will extract data and assess study quality using Quality Assessment of Diagnostic Accuracy Studies tool. RevMan 5.3 software will be utilized for data pooling and statistical analysis.

Results: This study will be performed to assess the clinical value of HFUCT for the diagnosis of TT, and will provide an evidence-based synthesis for clinical application and further study.

Conclusion: Summary of this study will provide the latest evidence to determine whether HFUCT can be used for TT diagnosis accurately.

Study registration: INPLASY202040022.

Abbreviations: CCS = case-controlled studies, HFUCT = high-frequency ultrasound combined computed tomography, <math>TT = thyroid tumor.

Keywords: computed tomography, high-frequency ultrasound, sensitivity, specificity, thyroid tumor

1. Introduction

Thyroid tumor (TT) is a very common disease, which consists of benign tumors and malignant tumors (thyroid cancer).^[1-5] It

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

The authors report no conflicts of interest.

This study was supported by Xianyang Science and Technology Bureau Scientific Research Project (2014K04-05), and Zhejiang Provincial Traditional Chinese Medicine Administration Research Project (2020ZB221). The funding supportor was not allowed to involve any sections of this study.

^a Department of Ultrasound, ^b Department of Radiology, Ningbo Municipal Hospital of TCM, Ningbo, China.

* Correspondence: Wei Tao, Department of Radiology, Ningbo Municipal Hospital of TCM, No. 819 Liyuan North Road, Haishu District, Ningbo 315000, China (e-mail: 70225027@qq.com).

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Zhang Lh, Chen G, Tao W. Can high frequency ultrasound combined computed tomography accurately diagnose thyroid tumor? a protocol of systematic review and meta-analysis. Medicine 2020;99:20 (e20180).

Received: 6 April 2020 / Accepted: 7 April 2020

http://dx.doi.org/10.1097/MD.000000000020180

increases with age and is present in almost 10% of adult population,^[5] in which, 95% of TT is benign, and 5% of it is malignant.^[5] The differential diagnosis of TT is very crucial for the clinical practice.^[6–8] Thus, it is very important to diagnose TT at early stage.^[9–11]

Previous studies have reported that high-frequency ultrasound combined computed tomography (HFUCT) can help to diagnose TT.^[12–18] However, no study has been undertaken systematically to examine the clinical value of HFUCT for the diagnosis of TT. Therefore, this systematic review will examine the clinical value of HFUCT for TT diagnosis.

2. Methods

2.1. Objective

This study aims to check the clinical value of HFUCT for the diagnosis of TT.

2.2. Study registration

We have registered this study on INPLASY202040022. We will report the results of this study according to the guideline of Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol statement.^[19]

2.3. Eligible criteria for including studies

2.3.1. Type of studies. We will only consider case-controlled studies on assessing the clinical value of HFUCT for the diagnosis of TT. However, we will exclude any other studies, such as animal studies, case studies, and nonclinical studies.

2.3.2. *Type of participants.* We will include studies of reporting patients with histological-proven TT.

2.3.3. *Type of index test.* Index test: We will include studies using HFUCT for the diagnosis of TT in the experimental group.

Reference test: We will include patients with histologicalproven TT in the control group.

2.3.4. Type of outcome measurements. The primary outcomes are sensitivity and specificity. The secondary outcomes are positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio.

2.4. Information sources and search strategy

2.4.1. Electronic searches. We will include any types of studies on assessing the clinical value of HFUCT for diagnosis of TT from any time period published to the present from the following databases: Cochrane Library, EMBASE, PUBMED, SCOPUS, Web of Science, OpenGrey, Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, and China National Knowledge Infrastructure. No limitations of language and publication status will be imposed. We will present search strategy for Cochrane Library in Table 1. We will also adapt similar search strategies to other electronic databases.

2.4.2. Other resources. We will also check reference lists of other relevant reviews, clinical trial registry, and conference proceedings.

2.5. Data records and analysis

2.5.1. Selection process of studies. We will export all citations from the searched resources to the Endnote 7.0, and we will remove any duplicated studies. Two authors will independently review all titles and abstracts to check whether they meet the eligibility criteria for inclusion, and all irrelevant studies will be excluded. Then, full-text articles for studies that fulfill the review criteria will be obtained and judged. The reasons for all excluded studies will be noted. The whole process of study selection will be shown in a flowchart. Any discrepancies at either the initial or full-text screening between 2 authors will be solved or consulted by a third author through discussion when necessary.

2.5.2. Data collection and management. Two authors will independently extract information from each selected study based on the previous designed sheet for data extraction. If there are any discrepancies between 2 authors, a third experienced author will be consulted to solve the different opinions. We will extract the following data: title, first author, publication time, location, patient characteristics, inclusion and exclusion criteria, study method, index test, refer test, outcomes, and funding information. If any insufficient information occurs, we will contact corresponding authors to inquire those data.

2.6. Study quality assessment

We will use Quality Assessment of Diagnostic Accuracy Studies tool to assess study quality for each included study.^[20] This tool is utilized for evaluating diagnostic accuracy for all included studies. Two authors will independently assess the study quality, and any divergences between 2 authors will be consulted by a third author to make final decision.

2.7. Statistical analysis

We will use RevMan V.5.3 software to synthesize the data and to perform data analysis.

We will calculate outcome data using descriptive statistics and 95% confidence intervals.

 I^2 statistic will be used to check the degree of statistical heterogeneity among included studies with the guide judgments: $I^2 \le 50\%$ indicating low heterogeneity, whereas $I^2 > 50\%$ exerting obvious heterogeneity. We will pool the data using a fixed-effect model, and we will consider performing a meta-analysis to calculate pooled effect of outcome measurements if those eligible studies are sufficiently homogeneous ($I^2 \le 50\%$). Otherwise, a random-effect model will be used and a subgroup analysis will be carried out to identify the reasons that may cause obvious heterogeneity.

2.8. Additional analysis

2.8.1. Subgroup analysis. We will operate a subgroup analysis based on the characteristics of different study or patient, comparators, and outcomes.

2.8.2. Sensitivity analysis. We will plan to perform a sensitivity analysis by removing low quality studies to check the robustness of outcome results.

Table						
Search	str	ategy	of	Cochrane	Librar	y.

_

Number

Search terms

Number	Search terms					
1	Mesh descriptor: (thyroid neoplasms) explode all trees					
2	((thyroid *) or (cancer *) or (neoplasms *) or (tumor *) or (tumour *) or (neoplas *)):ti, ab, kw					
3	0r 1–2					
4	MeSH descriptor: (tomography, x-ray computed) explode all trees					
5	(high frequency ultrasound) explode all trees					
6	((tomography)) or (computed)) or (ultrasound)) or ((ultrasonography)) or (medical ultrasound)) or (frequency) or (sensitivity)) or (specificity))					
7	0r 4–6					
8	MeSH descriptor: (case-control studies) explode all trees					
9	((case-control [*]) or (studies [*]) or (trials [*]) or (case [*]) or (control [*]) or (study [*])):ti, ab, kw					
10	Or 8–9					
11	3 and 7 and 10					

2.9. Ethics and dissemination

This study does not need ethical approval because it will not analyze individual patient data. The results of this study will be submitted on a peer-reviewed journal.

3. Discussion

This study will provide an up-to-date evidence to examine the clinical value of HFUCT for the diagnosis of TT through primary and secondary outcomes assessment. To our best knowledge, this is the first study to focus on the validity of HFUCT diagnoses in TT. This study will summarize the most recent evidence on the clinical value of HFUCT for the diagnosis of TT. Its results may provide useful and up-to-date findings to inform researchers on the validity of using HFUCT in the future research.

Author contributions

Conceptualization: Lin-hua Zhang, Gang Chen, Wei Tao.

Data curation: Gang Chen, Wei Tao.

Formal analysis: Lin-hua Zhang, Gang Chen, Wei Tao.

Funding acquisition: Wei Tao.

Investigation: Wei Tao.

Methodology: Lin-hua Zhang, Gang Chen.

Project administration: Wei Tao.

Resources: Lin-hua Zhang, Gang Chen.

Software: Lin-hua Zhang, Gang Chen.

Supervision: Wei Tao.

Validation: Lin-hua Zhang, Gang Chen, Wei Tao.

Visualization: Lin-hua Zhang, Gang Chen, Wei Tao.

Writing – original draft: Lin-hua Zhang, Gang Chen, Wei Tao.
Writing – review & editing: Lin-hua Zhang, Gang Chen, Wei Tao.

References

- Miyakawa M. Diagnostic imaging of thyroid tumor. Nihon Rinsho 2012;70:1900–7.
- [2] Brierley JD, Asa SL. Gospodarowicz MK. Thyroid cancer. Prognostic Factors in Cancer. New York: Wiley-Liss, Inc; 2001;195–208.

- [3] Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicularcell neoplasia. Nat Rev Cancer 2006;6:292–306.
- [4] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11–30.
- [5] Sherman SI. Thyroid carcinoma. Lancet 2003;361:501-11.
- [6] He L, Long LR, Antani S, et al. Histology image analysis for carcinoma detection and grading. Comput Methods Programs Biomed 2012;107: 538–56.
- [7] Barker J, Hoogi A, Depeursinge A, et al. Automated classification of brain tumor type in whole-slide digital pathology images using local representative tiles. Med Image Anal 2016;30:60–71.
- [8] Miyakawa M. Destructive thyroiditis-diffuse thyroid disease for the differentiation from thyroid tumor. Nihon Rinsho 2011;69(suppl 2): 324-31.
- [9] Nakamura H. Points in the guidelines for the management of thyroid tumor. Nihon Rinsho 2011;69(suppl 2):248–53.
- [10] Kameyama K, Ito K, Takami H. Pathology of benign thyroid tumor. Nihon Rinsho 2007;65:1973–8.
- [11] Król R, Heitzman M, Pawlicki J, et al. Follicular thyroid tumor as a diagnostic and therapeutic problem. Postepy Hig Med Dosw (Online) 2004;58:490–4.
- [12] Qiu YG. Analysis of the clinical value of high-frequency ultrasound combined with CT in the diagnosis of cervical lymph node metastasis of thyroid tumors. Imag Res Med Appl 2020;4:173–5.
- [13] Chen XH, Jiang H, Zhang Z. Clinical value of high-frequency ultrasound combined with CT in the diagnosis of cervical lymph node metastasis of thyroid tumors. Chinese J CT MRI 2019;17:36–8.
- [14] Zhang HQ, Yang M. The value of high-frequency ultrasound combined with spiral CT in the evaluation and diagnosis of thyroid cancer. Chinese J Clin Oncol Rehabil 2019;26:548–50.
- [15] Bai MZ, Gao B, Lv XH. The application value of high-frequency ultrasound combined with CT in the clinical diagnosis of thyroid papillary carcinoma. Chinese J CT MRI 2019;17:53–5.
- [16] Cao YM, Zhou SP, Hu T, et al. Application value of high-frequency ultrasound combined with spiral CT in the evaluation and diagnosis of thyroid cancer. J Pract Cancer 2018;33:169–71.
- [17] Wang YD, Wang Y, Qin QM, et al. The value of high-frequency ultrasound diagnosis of PET /CT high uptake thyroid nodules. Shanghai Med Imag 2008;2:97–8.
- [18] Guan YB, Zeng QS, Wu XM, et al. A comparative study of the value of spiral CT and high-frequency ultrasound in the diagnosis of thyroid cancer. Chinese J Med Imag 2005;2:136–8.
- [19] Shamseer L, Moher D, Clarke M, et al. PRISMA-P GroupPreferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349: g7647.
- [20] Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529–36.
- [21] Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005;58: 882–93.